EFFECTS OF GENISTEIN, ESTROGEN AND PROGESTERONE THERAPIES ON BLADDER MORPHOLOGY AND M2, M3 RECEPTOR EXPRESSIONS IN OOPHORECTOMIZED RATS
[ X ]
Date
2014
Journal Title
Journal ISSN
Volume Title
Publisher
Carbone Editore
Access Rights
info:eu-repo/semantics/closedAccess
Abstract
Aims: Investigating the effects of estrogen, estrogen/progesterone combination and genistein therapy on the expression of M2 and M3 receptors located on bladder walls and comparing the morphological and degenerative changes exerted on bladder walls. Materials and methods: A total of 50 adult Sprague-Dawley female rats were randomly divided into five groups. Rats other than the sham group were ovariectomized. OVX group (control group) received water, OVX+G group received 10 mg/kg genistein, OVX+E group received 0.014 mg/kg 17-beta estradiol, OVX+E+P group received 0.014 mg/kg 17-beta estradiol plus 0.028 mg/kg drospirenone per day. Results: When compared with the sham group, in the OVX group higher collagen fibre (CF): smooth muscle (SM) ratio, relatively increased fibrosis, oedema, space between detrusor smooth muscle fascicles, cytoplasmic vacuoles, and total M2, and M3 expression were observed. Relative to the OVX group, decreased CF: SM ratio and fibrosis in the OVX+G, OVX+E, and OVX+E+P groups, decreased oedema, spaces between detrusor muscle fascicles and cytoplasmic vacuoles in the OVX+G group and lesser total M2, and M3 expression in the OVX+G, OVX+E and OVX+E+P groups were observed. Conclusion: Genistein therapy regresses unfavourable morphological changes effecting postmenopausal bladder and increases in M2 and M3 receptor expression more effectively than estrogen and estrogen/progesterone combination. Besides, genistein therapy almost completely regresses degenerative changes; however, estrogen and estrogen/progesterone combination therapies do not improve these degenerative changes except for fibrosis. We think that genistein will favourably contribute both to the conduction of more comprehensive studies in the future concerning its use in postmenopausal urinary incontinence where estrogen and estrogen/progesterone combination therapies do not provide any improvement and etiopathogenesis of urinary incontinence.
Description
Keywords
Urinary Incontinence, Genistein, Estrogen, Menopause, Oophorectomized Rat, Muscarinic Receptor
Journal or Series
Acta Medica Mediterranea
WoS Q Value
Q4
Scopus Q Value
Volume
30
Issue
4
